From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
Location of tumor bank | Quebec | Ontario | Manitoba | Alberta | British Columbia | Total | |
---|---|---|---|---|---|---|---|
Total cases | 976 | 330 | 242 | 17 | 479 | 2046 | |
Histotype | BOT | 9 | 4 | 7 | 0 | 3 | 23 |
HGSC | 603 | 199 | 120 | 10 | 314 | 1246 | |
EC | 132 | 56 | 31 | 3 | 73 | 295 | |
LGSC | 52 | 24 | 19 | 0 | 8 | 103 | |
CCC | 123 | 37 | 36 | 1 | 62 | 259 | |
MC | 43 | 1 | 28 | 2 | 14 | 88 | |
other | 14 | 8 | 1 | 1 | 4 | 29 | |
Age (mean years)a | at diagnosis | 63 | 60 | 61 | 61 | 62 | 62 |
at end of follow-up | 66 | 64 | 65 | 66 | 66 | 65 | |
Year of diagnosis (range) | 1992–2015 | 1996–2013 | 2012–2015 | 1998–2015 | 1998–2013 | 1992–2015 | |
Follow-up (mean, months) | 54(0–270) | 51(0–168) | 32(9–49) | 49(0–181) | 47(0–173) | 48(0–270) | |
Survival ratea | Disease specific survival | 30% | 41% | 73% | 36% | 29% | 33% |
5-years survival rate | 31% | 40% | NA | 42% | 33% | 34% | |
Long Term Survival rate [> 10 years] | 9% | 7% | NA | 12% | 6% | 8% | |
Treatment type | none | 47 | 5 | 55 | 0 | 23 | 130 |
carboplatin+taxol | 690 | 238 | 160 | 15 | 351 | 1454 | |
cisplatin+taxol | 40 | 28 | 9 | 0 | 20 | 97 | |
platinum | 21 | 21 | 15 | 0 | 45 | 102 | |
platinum+other | 47 | 2 | 1 | 0 | 6 | 56 | |
taxol | 3 | 0 | 0 | 0 | 0 | 3 | |
other | 15 | 6 | 0 | 0 | 1 | 22 | |
Total | 863 | 300 | 240 | 15 | 446 | 1864 | |
% response to treatmenta | 69% | 84% | 90% | 91% | 71% | 75% | |
BRCA mutation carrier status | non carriers | 306 | 27 | 6 | 9 | 137 | 485 |
carriers | 58 | 16 | 2 | 4 | 33 | 113 | |
total | 370 | 33 | 8 | 13 | 170 | 594 | |
% carriers | 16% | 48% | 25% | 31% | 19% | 19% |